PLK1 and nasopharyngeal carcinoma: Indeed, nasopharyngeal carcinoma and diffuse midline glioma cells have shown increased sensitivity to co-inhibition of PLK1 and AURKA compared to BI-2536 or AURKA inhibitors as a single agent [33–35].